{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:59:00Z","timestamp":1771952340299,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"\u201cLeading Geese\u201d Research and Development Plan of Zhejiang Province","award":["NO. 2024C03190"],"award-info":[{"award-number":["NO. 2024C03190"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["NO. 82274273"],"award-info":[{"award-number":["NO. 82274273"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06815-6","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T03:18:04Z","timestamp":1770175084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma exchange combined with anti-B-cell therapy enables comparable outcomes between DSA-positive and DSA-negative aplastic anemia after haplo-HSCT: a propensity-score-matched cohort study"],"prefix":"10.1007","volume":"105","author":[{"given":"Zhengwei","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuechao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dijiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baodong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"6815_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1756-8722-5-10","volume":"5","author":"M Lv","year":"2012","unstructured":"Lv M, Huang XJ (2012) Allogeneic hematopoietic stem cell transplantation in china: where we are and where to go. J Hematol Oncol 5:10","journal-title":"J Hematol Oncol"},{"issue":"8","key":"6815_CR2","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","volume":"26","author":"A D\u2019Souza","year":"2020","unstructured":"D\u2019Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S et al (2020) Current use of and trends in hematopoietic cell transplantation in the united States. Biol Blood Marrow Transpl 26(8):e177\u2013e182","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"6815_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41408-022-00729-y","volume":"12","author":"K Raj","year":"2022","unstructured":"Raj K, Eikema DJ, Sheth V, Koster L, de Wreede LC, Blaise D et al (2022) Comparison of outcomes for HLA-matched sibling and haplo-identical donors in myelodysplastic syndromes: report from the chronic malignancies working party of EBMT. Blood Cancer J 12(9):140","journal-title":"Blood Cancer J"},{"issue":"15","key":"6815_CR4","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1182\/blood-2009-10-249219","volume":"116","author":"M Takanashi","year":"2010","unstructured":"Takanashi M, Atsuta Y, Fujiwara K, Kodo H, Kai S, Sato H et al (2010) The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 116(15):2839\u20132846","journal-title":"Blood"},{"issue":"8","key":"6815_CR5","first-page":"687e1","volume":"27","author":"Y Xie","year":"2021","unstructured":"Xie Y, Parekh J, Tang Z, Wu D, Wu X (2021) Donor-specific antibodies and primary graft failure in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transpl Cell Ther 27(8):687e1\u2013687e7","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"6815_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41409-023-01932-6","volume":"58","author":"Y Huang","year":"2023","unstructured":"Huang Y, Luo C, Wu G, Huang X, Ding Y, Huang Z et al (2023) Effects of donor-specific antibodies on engraftment and long-term survival after allogeneic hematopoietic stem cell transplantation-a systematic review and meta-analysis. Bone Marrow Transplant 58(5):544\u201351","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"6815_CR7","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/TP.0000000000001391","volume":"101","author":"EY Cheng","year":"2017","unstructured":"Cheng EY, Everly MJ, Kaneku H, Banuelos N, Wozniak LJ, Venick RS et al (2017) Prevalence and clinical impact of donor-specific alloantibody among intestinal transplant recipients. Transplantation 101(4):873\u201382","journal-title":"Transplantation"},{"issue":"5","key":"6815_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","volume":"53","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E et al (2018) The european society for blood and marrow transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 53(5):521\u201334","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"6815_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40487-024-00283-6","volume":"12","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Chen YL, Huang XY, Chang YJ (2024) Desensitization strategies for donor-specific antibodies in HLA-mismatched stem cell transplantation recipients: what we know and what we do not know. Oncol Ther 12(3):375\u2013394","journal-title":"Oncol Ther"},{"issue":"1","key":"6815_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.htct.2022.11.009","volume":"46","author":"M Chowdhry","year":"2024","unstructured":"Chowdhry M, Yadav A, Sharma V, Agrawal S (2024) Role of therapeutic plasma exchange as a desensitization therapy in human leukocyte antigen incompatible renal transplant patients: a single-center experience. Hematol Transfus Cell Ther 46(1):42\u201348","journal-title":"Hematol Transfus Cell Ther"},{"issue":"1","key":"6815_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/asheducation-2017.1.645","volume":"2017","author":"DE Gladstone","year":"2017","unstructured":"Gladstone DE, Bettinotti MP (2017) HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities. Hematol. Am Soc Hematol Educ Program 2017(1):645\u2013650","journal-title":"Am Soc Hematol Educ Program"},{"key":"6815_CR12","unstructured":"The european society for blood and marrow transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation - PubMed. [cited 2025 May 31]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29335625\/"},{"key":"6815_CR13","doi-asserted-by":"crossref","first-page":"4025073","DOI":"10.1155\/2016\/4025073","volume":"2016","author":"P Kongtim","year":"2016","unstructured":"Kongtim P, Cao K, Ciurea SO (2016) Donor specific anti-HLA antibody and risk of graft failure in haploidentical stem cell transplantation. Adv Hematol 2016:4025073","journal-title":"Adv Hematol"},{"key":"6815_CR14","doi-asserted-by":"crossref","unstructured":"Mh J, Ht G, Km MA, Ew WDW et al (2015) C,. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. Mar [cited 2025 Mar 21];21(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25529383\/","DOI":"10.1016\/j.bbmt.2014.12.035"},{"issue":"3","key":"6815_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3324\/haematol.13829","volume":"94","author":"P Scheinberg","year":"2009","unstructured":"Scheinberg P, Wu CO, Nunez O, Scheinberg P, Boss C, Sloand EM et al (2009) Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 94(3):348\u201354","journal-title":"Haematologica"},{"key":"6815_CR16","doi-asserted-by":"crossref","unstructured":"Ae D, Ja MEJW, Bj TMS DS (2022) Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Lancet, Haematol Sept [cited 2025 Mar 21];9(9). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35907408\/","DOI":"10.1016\/S2352-3026(22)00206-X"},{"key":"6815_CR17","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide"},{"issue":"12","key":"6815_CR18","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/bmt.2012.79","volume":"47","author":"LP Xu","year":"2012","unstructured":"Xu LP, Liu KY, Liu DH, Han W, Chen H, Chen YH et al (2012) A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant 47(12):1507\u201312","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"6815_CR19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.bbmt.2019.02.020","volume":"25","author":"S Bramanti","year":"2019","unstructured":"Bramanti S, Calafiore V, Longhi E, Mariotti J, Crespiatico L, Sarina B et al (2019) Donor-specific anti-HLA antibodies in haploidentical stem cell transplantation with post-transplantation cyclophosphamide: risk of graft failure, poor graft function, and impact on outcomes. Biol Blood Marrow Transplant 25(7):1395\u2013406","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"6815_CR20","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1182\/bloodadvances.2021004862","volume":"5","author":"SO Ciurea","year":"2021","unstructured":"Ciurea SO, Al Malki MM, Kongtim P, Zou J, Aung FM, Rondon G et al (2021) Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv 5(20):4031\u20134043","journal-title":"Blood Adv"},{"issue":"8","key":"6815_CR21","doi-asserted-by":"publisher","first-page":"493.e1","DOI":"10.1016\/j.jtct.2023.05.014","volume":"29","author":"ACM Lima","year":"2023","unstructured":"Lima ACM, Getz J, do Amaral GB, Loth G, Funke VAM, Nabhan SK et al (2023) Donor-specific HLA antibodies are associated with graft failure and delayed hematologic recovery after unrelated donor hematopoietic cell transplantation. Transplant Cell Ther 29(8):493.e1-493.e10","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"6815_CR22","doi-asserted-by":"publisher","first-page":"902.e1","DOI":"10.1016\/j.jtct.2024.05.008","volume":"30","author":"X Wei","year":"2024","unstructured":"Wei X, Zhu W, Li J, Zhou S, Zhu Q, Ma X et al (2024) The role of pre-existing anti-HLA antibodies in severe aplastic anemia patients undergoing allogenic hematopoietic stem cell transplantation. Transplant Cell Ther 30(9):902.e1-902.e11","journal-title":"Transplant Cell Ther"},{"key":"6815_CR23","first-page":"8:84","volume":"1","author":"YJ Chang","year":"2024","unstructured":"Chang YJ, Zhao XY, Xu LP, Zhang XH, Wang Y, Han W et al (2015 July) Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol 10:8:84","journal-title":"J Hematol Oncol"},{"issue":"4","key":"6815_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcyt.2022.10.005","volume":"25","author":"T Jo","year":"2023","unstructured":"Jo T, Arai Y, Hatanaka K, Ishii H, Ono A, Matsuyama N et al (2023) Adverse effect of donor-specific anti-human leukocyte antigen (HLA) antibodies directed at HLA-DP\/-DQ on engraftment in cord blood transplantation. Cytotherapy 25(4):407\u201314","journal-title":"Cytotherapy"},{"issue":"1","key":"6815_CR25","doi-asserted-by":"publisher","first-page":"99.e1","DOI":"10.1016\/j.jtct.2023.10.015","volume":"30","author":"A Sadowska-Klasa","year":"2024","unstructured":"Sadowska-Klasa A, Dukat-Mazurek A, Zieli\u0144ska H, D\u0119bska-Zielkowska J, Piekarska A, Moszkowska G et al (2024) Incidence and role of recipient-specific antibodies in allogeneic hematopoietic cell transplantation from mismatched related donors. Transplant Cell Ther 30(1):99.e1-99.e10","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"6815_CR26","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.bbmt.2015.05.001","volume":"21","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y et al (2015) Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21(8):1392\u20138","journal-title":"Biol Blood Marrow Transplant"},{"key":"6815_CR27","doi-asserted-by":"publisher","first-page":"1043836","DOI":"10.1155\/2017\/1043836","volume":"2017","author":"X Zhao","year":"2017","unstructured":"Zhao X, Zhao X, Huo M, Fan Q, Pei X, Wang Y et al (2017) Donor-specific anti-human leukocyte antigen antibodies predict prolonged isolated thrombocytopenia and inferior outcomes of haploidentical hematopoietic stem cell transplantation. J Immunol Res 2017:1043836","journal-title":"J Immunol Res"},{"issue":"1","key":"6815_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"XH Zhang","year":"2021","unstructured":"Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M et al (2021) The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol 14(1):145","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6815_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","volume":"55","author":"SO Ciurea","year":"2020","unstructured":"Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ et al (2020) The European society for blood and marrow transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl 55(1):12\u201324","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"6815_CR30","doi-asserted-by":"publisher","first-page":"S232","DOI":"10.1016\/j.ajt.2025.07.510","volume":"25","author":"S Maruthamuthu","year":"2025","unstructured":"Maruthamuthu S, Gente GD, Rajalingam R (2025) High-affinity NK cell IgG receptors and de novo DSA are linked to poor kidney transplant outcomes. Am J Transpl 25(8):S232","journal-title":"Am J Transpl"},{"key":"6815_CR31","doi-asserted-by":"publisher","first-page":"13318","DOI":"10.3389\/ti.2024.13318","volume":"37","author":"M Chambon","year":"2024","unstructured":"Chambon M, Koenig A (2024) NK cells: not just followers but also initiators of chronic vascular rejection. Transplant Int 37:13318","journal-title":"Transplant Int"},{"key":"6815_CR32","doi-asserted-by":"publisher","first-page":"1005790","DOI":"10.3389\/fimmu.2022.1005790","volume":"13","author":"L Frischknecht","year":"2022","unstructured":"Frischknecht L, Deng Y, Wehmeier C, de Rougemont O, Villard J, Ferrari-Lacraz S et al (2022) The impact of pre-transplant donor specific antibodies on the outcome of kidney transplantation - data from the swiss transplant cohort study. Front Immunol 13:1005790","journal-title":"Front Immunol"},{"issue":"10","key":"6815_CR33","doi-asserted-by":"publisher","first-page":"698.e1","DOI":"10.1016\/j.jtct.2022.07.019","volume":"28","author":"ACM Lima","year":"2022","unstructured":"Lima ACM, Bonfim C, Getz J, do Amaral GB, Petterle RR, Loth G et al (2022) Untreated donor-specific HLA antibodies are associated with graft failure and poor survival after haploidentical transplantation with post-transplantation cyclophosphamide in pediatric patients with nonmalignant disorders. Transplant Cell Ther 28(10):698.e1-698.e11","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"6815_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/tan.14277","volume":"97","author":"ACM Lima","year":"2021","unstructured":"Lima ACM, Bonfim C, Getz J, Dornelles LN, do Amaral GB, Petterle RR et al (2021) The impact of donor-specific anti-human leukocyte antigen antibodies in salvage haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide in patients with nonmalignant disorders. Hla 97(6):493\u2013504","journal-title":"Hla"},{"issue":"12","key":"6815_CR35","doi-asserted-by":"publisher","first-page":"101336","DOI":"10.1016\/j.xcrm.2023.101336","volume":"4","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W et al (2023) Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies. Cell Rep Med 4(12):101336","journal-title":"Cell Rep Med"},{"issue":"7","key":"6815_CR36","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/s41409-020-0928-z","volume":"55","author":"YJ Chang","year":"2020","unstructured":"Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH et al (2020) Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. Bone Marrow Transplant 55(7):1326\u201336","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"6815_CR37","first-page":"1233","volume":"109","author":"N Ma","year":"2024","unstructured":"Ma N, Wu WB, Zhao XY, Xu LP, Zhang XH, Wang Y et al (2024) Targeting TFH cells is a novel approach for donor-specific antibody desensitization of allograft candidates: an in vitro and in vivo study. Haematologica 109(4):1233\u20131246","journal-title":"Haematologica"},{"issue":"2","key":"6815_CR38","first-page":"157","volume":"22","author":"U La Rocca","year":"2024","unstructured":"La Rocca U, Perrone MP, Piciocchi A, Barberi W, Gesuiti P, Laurenti L et al (2024) Donor specific anti-HLA antibodies in hematopoietic stem cell transplantation. Single center prospective evaluation and desensitization strategies employed. Blood Transfus = Trasfus Sangue 22(2):157\u2013165","journal-title":"Blood Transfus = Trasfus Sangue"},{"issue":"2","key":"6815_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41409-022-01868-3","volume":"58","author":"S Zhou","year":"2023","unstructured":"Zhou S, Ma X, Ma C, Zhu Q, Zhao Q, Li L et al (2023) Splenic irradiation combined with plasmapheresis and rituximab: a new option reducing donor-specific antibody in haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant 58(2):226\u20138","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"6815_CR40","first-page":"468","volume":"45","author":"L Li","year":"2024","unstructured":"Li L, Zhu WJ, Zhu Q, Zhou SY, Ma C, Wang J et al (2024) [The efficacy and safety of protein A immunoadsorption combined with rituximab treatment for highly sensitized patients undergoing haplo-hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi 45(5):468\u2013474","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi"},{"issue":"3","key":"6815_CR41","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1056\/NEJMoa0707894","volume":"359","author":"AA Vo","year":"2008","unstructured":"Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH et al (2008) Rituximab and intravenous immune Globulin for desensitization during renal transplantation. N Engl J Med 359(3):242\u2013251","journal-title":"N Engl J Med"},{"issue":"6","key":"6815_CR42","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/TP.0000000000000132","volume":"98","author":"MC Philogene","year":"2014","unstructured":"Philogene MC, Sikorski P, Montgomery RA, Leffell MS, Zachary AA (2014) Differential effect of bortezomib on HLA class I and class II antibody. Transplantation 98(6):660\u2013665","journal-title":"Transplantation"},{"issue":"2","key":"6815_CR43","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/j.bbmt.2018.10.018","volume":"25","author":"H Choe","year":"2019","unstructured":"Choe H, Gergis U, Hsu J, Phillips A, Shore T, Christos P et al (2019) Bortezomib and immune Globulin have limited effects on Donor-Specific HLA antibodies in haploidentical cord blood stem cell transplantation: detrimental effect of persistent haploidentical Donor-Specific HLA antibodies. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transpl 25(2):e60\u2013e64","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transpl"},{"issue":"7","key":"6815_CR44","doi-asserted-by":"publisher","first-page":"e23261","DOI":"10.1002\/jcla.23261","volume":"34","author":"R Zhang","year":"2020","unstructured":"Zhang R, He Y, Yang D, Jiang E, Ma Q, Pang A et al (2020) Combination treatment of rituximab and donor platelets infusion to reduce donor-specific anti-HLA antibodies for stem cells engraftment in haploidentical transplantation. J Clin Lab Anal 34(7):e23261","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"6815_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/bmt.2015.292","volume":"51","author":"H Yabe","year":"2016","unstructured":"Yabe H, Morimoto T, Takakura H, Okuya M, Ikegaya R, Kato S et al (2016) Post-transplantation-emerging anti-HLA DQA1\/DQB1 antibody possibly responsible for graft rejection after myeloablative-unrelated marrow grafting. Bone Marrow Transplant 51(4):601\u20133","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"6815_CR46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41409-021-01494-5","volume":"57","author":"M Carter","year":"2022","unstructured":"Carter M, Taniguchi M, Yang D, Arslan S, Shouse G, Ali H et al (2022) Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant 57(1):134\u20136","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"6815_CR47","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/bloodadvances.2023010362","volume":"8","author":"SJ Bracken","year":"2024","unstructured":"Bracken SJ, Suthers AN, DiCioccio RA, Su H, Anand S, Poe JC et al (2024) Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions. Blood Adv 8(3):667\u2013680","journal-title":"Blood Adv"},{"issue":"7","key":"6815_CR48","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1172\/JCI136225","volume":"130","author":"JI Cohen","year":"2020","unstructured":"Cohen JI (2020) Herpesvirus latency. J Clin Invest 130(7):3361\u20139","journal-title":"J Clin Invest"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06815-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:04:28Z","timestamp":1771949068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06815-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6815"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06815-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to the commencement of the study, all enrolled patients were informed that their clinical data might be utilized for medical research, and their written informed consent was obtained. Throughout the research process, the personal data of all patients was strictly handled in accordance with the principles of anonymity and confidentiality, being used solely for the purposes of this study. This experimental protocol was devised based on the ethical principles outlined in the Declaration of Helsinki. It was also approved by the Human Ethics Committee of the First Affiliated Hospital of Zhejiang Chinese Medical University (approval number 2025-KLS-513-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}